Immunotherapy of sarcomas

Current Opinion in Oncology

Volumn 25, Issue 4, 2013, Pages 390-397

  Goldberg, John M ^a,b  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MIAMI   (United States)

Author keywords

antibody; cancer immunotherapy; cancer vaccines; dendritic cells; sarcoma

Indexed keywords

CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DASATINIB; DENDRITIC CELL VACCINE; GEMCITABINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR VACCINE; HEAT SHOCK PROTEIN; IMIQUIMOD; IPILIMUMAB; PEPTIDE VACCINE; PROGRAMMED DEATH 1 LIGAND 1; SIPULEUCEL T; SOMATOMEDIN C RECEPTOR;

ADOPTIVE IMMUNOTHERAPY; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIGEN PRESENTING CELL; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CASTRATION RESISTANT PROSTATE CANCER; CHILDHOOD CANCER; CONNECTIVE TISSUE; DENDRITIC CELL; HUMAN; IMMUNE RESPONSE; LICENSING; LUNG METASTASIS; OSTEOSARCOMA; PRIORITY JOURNAL; REVIEW; SARCOMA; VACCINATION;

CLINICAL TRIALS AS TOPIC; COMBINED MODALITY THERAPY; HUMANS; IMMUNOTHERAPY; SARCOMA;

EID: 84879884723     PISSN: 10408746     EISSN: 1531703X     Source Type: Journal    
DOI: 10.1097/CCO.0b013e3283622c8a     Document Type: Review

References (45)

1. Pires de Camargo V, van de Rijn M, Maestro R, et al. Other targetable sarcomas. Semin Oncol 2009; 36:358-371.
2. Dematteo RP, Ballman KV, Antonescu CR, et al. Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. Lancet 2009; 373:1097-1104.
3. Granowetter L, Womer R, Devidas M, et al. Dose-intensified compared with standard chemotherapy for nonmetastatic Ewing sarcoma family of tumors: a children's oncology group study. J Clin Oncol 2009; 27:2536-2541.
4. Dagher R, Long LM, Read EJ, et al. Pilot trial of tumor-specific peptide vaccination and continuous infusion interleukin-2 in patients with recurrent Ewing sarcoma and alveolar rhabdomyosarcoma: an inter-institute NIH study. Med Pediatr Oncol 2002; 38:158-164. (Pubitemid 34171069)
5. Robbins PF, Morgan RA, Feldman SA, et al. Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J Clin Oncol 2011; 29:917-924.
6. Goldberg J, Grier HE, Fisher DE, et al. GM-CSF secreting autologous tumor vaccines for the microphthalmia transcription factor associated tumors. [Abstract]. 2-5 December 2008. An AACR Special Conference in Cancer Research, Tumor Immunology: New Perspectives.
7. Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines. Nat Med 2004; 10:909-915. (Pubitemid 39273730)
8. Dranoff G. GM-CSF-based cancer vaccines. Immunol Rev 2002; 188:147-154. (Pubitemid 35398872)
9. Strbo N, Podack ER. Secreted heat shock protein gp96-Ig: an innovative vaccine approach. Am J Reprod Immunol 2008; 59:407-416. (Pubitemid 351524230)
10. Arndt CA, Koshkina NV, Inwards CY, et al. Inhaled granulocyte-macrophage colony stimulating factor for first pulmonary recurrence of osteosarcoma: effects on disease-free survival and immunomodulation. a report from the Children's Oncology Group. Clin Cancer Res 2010; 16:4024-4030.
11. Gorlick R, Janeway K, Lessnick S, et al. Children's oncology group's 2013 blueprint for research: bone tumors. Pediatr Blood Cancer 2013; 60:1009-1015.
12. Dranoff G. CTLA-4 blockade: unveiling immune regulation. J Clin Oncol 2005; 23:662-664. (Pubitemid 46224164)
13. Coley WB II. Contribution to the knowledge of sarcoma. Ann Surg 1891; 14:199-220.
14. Goorin AM, Delorey MJ, Lack EE, et al. Prognostic significance of complete surgical resection of pulmonary metastases in patients with osteogenic sarcoma: analysis of 32 patients. J Clin Oncol 1984; 2:425-431. (Pubitemid 14075972)
15. Kleinerman ES, Gano JB, Johnston DA, et al. Efficacy of liposomal muramyl tripeptide (CGP 19835A) in the treatment of relapsed osteosarcoma. Am J Clin Oncol 1995; 18:93-99.
16. Meyers PA, Schwartz CL, Krailo M, et al. Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate. J Clin Oncol 2005; 23:2004-2011. (Pubitemid 46211380)
17. Meyers PA, Schwartz CL, Krailo MD, et al. Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival-a report from the Children's Oncology Group. J Clin Oncol 2008; 26:633-638. (Pubitemid 351264359)
18. Capitini CM, Fry TJ, Mackall CL. Cytokines as adjuvants for vaccine and cellular therapies for cancer. Am J Immunol 2009; 5:65-83.
19. Mackall CL, Rhee EH, Read EJ, et al. A pilot study of consolidative immunotherapy in patients with high-risk pediatric sarcomas. Clin Cancer Res 2008; 14:4850-4858.
20. Olmos D,Martins AS, Jones RL, et al. Targeting the insulin-like growth factor 1 receptor in Ewing's sarcoma: reality and expectations. Sarcoma 2011; 2011:402508.
21. Pappo AS, Patel SR, Crowley J, et al. R1507, a monoclonal antibody to the insulin-like growth factor 1 receptor, in patients with recurrent or refractory Ewing sarcoma family of tumors: results of a phase II Sarcoma Alliance for Research through Collaboration study. J Clin Oncol 29:4541-4547.
22. Yu AL, Gilman AL, Ozkaynak MF, et al. Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. N Engl J Med 2010; 363:1324-1334.
23. Carballido E, Fishman M. Sipuleucel-T: prototype for development of antitumor vaccines. Curr Oncol Rep 2011; 13:112-119.
24. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363:711-723.
25. Brinkrolf P, Landmeier S, Altvater B, et al. A high proportion of bone marrow T cells with regulatory phenotype (CD4pCD25hiFoxP3p) in Ewing sarcoma patients is associated with metastatic disease. Int J Cancer 2009; 125:879-886.
26. Salama AK, Hodi FS. Cytotoxic T-lymphocyte-associated antigen-4. Clin Cancer Res 2011; 17:4622-4628.
27. Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012; 366:2443-2454.
28. Kawaguchi S, Tsukahara T, Ida K, et al. SYT-SSX breakpoint peptide vaccines in patients with synovial sarcoma: a study from the Japanese Musculoskeletal Oncology Group. Cancer Sci 2012; 103:1625-1630.
29. Indelicato DJ, Finkelstein SE. Dendritic cell immunotherapy in soft tissue sarcoma. Immunotherapy 2012; 4:1023-1029.
30. Gilboa E. DC-based cancer vaccines. J Clin Invest 2007; 117:1195-1203. (Pubitemid 46718404)
31. Nair S, McLaughlin C, Weizer A, et al. Injection of immature dendritic cells into adjuvant-treated skin obviates the need for ex vivo maturation. J Immunol 2003; 171:6275-6282. (Pubitemid 37467251)
32. Okada H, Kalinski P, Ueda R, et al. Induction of CD8p T-cell responses against novel glioma-associated antigen peptides and clinical activity by vaccinations with {alpha}-type 1 polarized dendritic cells and polyinosinicpolycytidylic acid stabilized by lysine and carboxymethylcellulose in patients with recurrent malignant glioma. J Clin Oncol 2011; 29:330-336.
33. Van Gool S, Maes W, Ardon H, et al. Dendritic cell therapy of high-grade gliomas. Brain Pathol 2009; 19:694-712.
34. Soiffer R, Hodi FS, Haluska F, et al. Vaccination with irradiated, autologous melanoma cells engineered to secrete granulocyte-macrophage colony-stimulating factor by adenoviral-mediated gene transfer augments antitumor immunity in patients with metastatic melanoma. J Clin Oncol 2003; 21:3343-3350. (Pubitemid 46606268)
35. Hodi FS, Butler M, Oble DA, et al. Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients. Proc Natl Acad Sci USA 2008; 105:3005-3010. (Pubitemid 351723658)
36. Serafini P, Borrello I, Bronte V. Myeloid suppressor cells in cancer: recruitment, phenotype, properties, and mechanisms of immune suppression. Semin Cancer Biol 2006; 16:53-65. (Pubitemid 43139709)
37. Serafini P, Carbley R, Noonan KA, et al. High-dose granulocyte-macrophage colony-stimulating factor-producing vaccines impair the immune response through the recruitment of myeloid suppressor cells. Cancer Res 2004; 64:6337-6343. (Pubitemid 39129439)
38. Goldberg JM, Zidan A-A, Siddiqi R, et al. Circulating myeloid-derived suppressor cells in pediatric solid tumor patients. J Clin Oncol 2012; 30 Suppl:abstr. 9565.
39. Finkelstein SE, Iclozan C, Bui MM, et al. Combination of external beam radiotherapy (EBRT) with intratumoral injection of dendritic cells as neoadjuvant treatment of high-risk soft tissue sarcoma patients. Int J Radiat Oncol Biol Phys 2012; 82:924-932.
40. Burdach S, van Kaick B, Laws HJ, et al., Allogeneic and autologous stem-cell transplantation in advanced Ewing tumors. An update after long-term followup from two centers of the European Intergroup study EICESS. Stem-Cell Transplant Programs at Dusseldorf University Medical Center, Germany and St. Anna Kinderspital, Vienna, Austria. Ann Oncol 2000; 11:1451-1462.
41. Pastor F, Kolonias D, Giangrande PH, Gilboa E. Induction of tumour immunity by targeted inhibition of nonsense-mediated mRNA decay. Nature 2010; 465:227-230.
42. Reyes-Reyes EM, Teng Y, Bates PJ. A new paradigm for aptamer therapeutic AS1411 action: uptake by macropinocytosis and its stimulation by a nucleolin- dependent mechanism. Cancer Res 2010; 70:8617-8629.
43. Maki RG, Jungbluth AA, Gnjatic S, et al. A pilot study of anti-CTLA4 antibody ipilimumab in patients with synovial sarcoma. Sarcoma 2013; 2013:168145.
44. Chen DS, Irving BA, Hodi FS. Molecular pathways: next-generation immunotherapy-inhibiting programmed death-ligand 1 and programmed death-1. Clin Cancer Res 2012; 18:6580-6587.
45. Pastor F, Kolonias D, McNamara JO 2nd, Gilboa E. Targeting 4-1BB costimulation to disseminated tumor lesions with bi-specific oligonucleotide aptamers. Mol Ther 2011; 19:1878-1886. Institute